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One can argue forever what precise per-
centage of the world’s population use local 
and traditional medicines. These herbal 
(or mineral or fungal or occasionally ani-
mal) medical products form systems of 
knowledge and practice that have been 
transmitted over centuries and which con-
tinuously change. However, there can be no 
doubt that the majority of humans either 
rely on such products (often due to lack 
of other alternatives) or that herbal medi-
cines are chosen consciously as an alter-
native to mainstream medicine. In some 
cases this knowledge is documented in an 
extensive historical written body of schol-
arly and applied writings. Traditions like 
“Traditional” Chinese, Ayurvedic, Unani, 
Jamu, Kampo, Iranian, Aztec or various 
forms of European and Arabic medicine 
are well known examples. In other regions 
we rely on the efforts of researchers past 
and present to document such knowledge 
and to critically analyze the data. It is now 
a commonplace that such “traditional 
knowledge” is disappearing fast, but in fact 
it is simply changing under the pressures 
of a globalizing world.
Frontiers in Ethnopharmacology is 
a worldwide, open access platform for 
bioscientific, clinical and sociocultural 
research on medicinal and food plants 
as well as other natural substances used 
throughout the world. This multidisci-
plinary approach is an essential basis for 
the use of these resources in tomorrow’s 
medicines. Neglected diseases, including 
such common ones as vector-borne ones, 
diarrhea or tuberculosis are still commonly 
treated with herbal medicines. There is a 
growing use of plants to manage or treat 
AIDS/HIV or other emerging or fast spread-
ing diseases (like viral respiratory diseases. 
Novel treatment strategies are needed for 
all diseases and in recent years herbal med-
icines from such traditions have received 
particular attention in the management 
(prevention or treatment) of chronic dis-
eases like diabetes, chronic CNS disorders 
and many forms of cancer. Lastly, there are 
major gaps in our knowledge both about the 
general safety and the interaction potential 
of these medicines.
A core challenge in pharmacology is 
the scientific study of the complex prod-
ucts derived from such traditions. Extracts 
obtained from plants, fungi or animals pose 
some unique challenges: they are multi-
component mixtures of active, partially 
active and inactive substances and the activ-
ity is often not on a single target. Because of 
this complexity, extracts often vary and thus 
the pharmacological effects cannot always 
be reproduced. And they offer unique 
opportunities. The structural diversity and 
chemical complexity of natural products 
is unbeaten. In areas like anti-cancer and 
anti-parasitic medications as well as in 
pain management, natural products form 
the core of human’s treatment options: 
“Artemisinin, triptolide, celastrol, capsaicin, 
and curcumin are “poster children” for the 
power and promise of turning traditional 
medicines into modern drugs. However, 
their stories highlight the ongoing inter-
disciplinary research efforts that continue 
to be necessary to realize the pharmaceu-
tical potential of traditional therapeutics” 
(Corson and Crews, 2007). While a lot of 
research is going on in the field of ethnop-
harmacology, much of this work is either 
poorly accessible or it lacks a critical and 
state-of-the art approach. This is one of the 
grand challenges in ethnopharmacology.
Pharmacology has been influenced 
tremendously by its links with studies on 
“natural products” (Malone, 1983; Heinrich, 
2010). For example, in the 19th century the 
first systematic studies on the pharmacologi-
cal effects of curare were conducted by the 
French physiologist/pharmacologist Claude 
Bernard (1813–1878). This is a classical 
example of an in vivo approach which – in 
combination with ex vivo approaches – 
dominated pharmacology until the 
advent of screening oriented and later more 
mechanistic in vitro experiments (Heinrich, 
2010). Of course, the serendipitous discov-
ery of the penicillins (Alexander Flemming, 
1881–1955) in 1928 is the classical example 
of how successful science has been in refin-
ing and downscaling the experimental set-
ups and in focusing these on a single target. 
A further core step were the development 
of in vitro methods to screen for novel anti-
cancer agents. This line of research started 
in the late 1950’s at the US NCI/NIH and 
resulted in the famous discoveries of the 
vinca-alkaloids, taxol, camptothecin and 
podophyllum-derivatives as medicinal 
agents as well as a much more detailed 
understanding of their mechanism of action 
(in two cases associated with Monroe Wall 
(1916–2002), Mansukhlal C. Wani (* 1925) 
and co- workers, Sneader, 1985).
Since the 1970’s in vitro methods became 
more and more important. A wide range 
of targets were explored (e.g., antimicrobial 
effects, Ieven et al., 1979; anti-viral effects, 
Van den Berghe et al., 1978, 1986; mon-
amine oxidase inhibitors, Suzuki et al., 1981, 
angiotensin inhibitors, Elbl and Wagner, 
1991; anti-inflammatory and anti-allergic 
effects, Wagner, 1989). Microplate-based 
routine methods and other approaches to 
miniaturize sample size marked a new step 
in these developments, also allowing for an 
increase in the overall throughput of sam-
ples (Suzuki et al., 1981). Another approach 
was developed from the 1980’s onwards by 
combining thin layer chromatography tech-
niques first with overlay techniques to detect 
anti-microbiological activity and then the 
use of microbial or chemical spraying rea-
gents in order to detect biological activities. 
Examples include the use of Bacillus subtilis 
(Hamburger and Cordell, 1987) or the use 
of DPPH as a model for anti-oxidant effects. 
Bioautography had originally been used to 
study, for example, the strength and purity 
of penicillins, but was now explored in the 
systematic ethnopharmacological study 
of traditional and local medicinal plants. 
The search for anti-protozoal agents was 
also pushed forward by the use of in vitro 
techniques, which started in the early 1980’s 
(Wright and Phillipson, 1990). Since the 
1980’s a wide range of in vitro studies were 
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Therefore, where are the opportunities 
and challenges for the future? We need 
studies at all levels from the critical study 
of traditional and local knowledge systems 
(Etkin, 1988, Heinrich et al., 2009), to the 
screening of such plants in primary assays, 
the detailed mechanistic study of an extract’s 
or a natural compound’s pharmacology and 
toxicology to the clinical evaluation of their 
effectiveness (Corson and Crews, 2007; cf. 
Graz et al., 2010) or studies on the public 
health implications of using (or not using) 
such medicines. All this forms the basis for 
an evidence-based approach to these “natu-
ral medicines”. In general terms the safety of 
such products is considered to be more and 
more a central area of research. In recent 
years some therapeutic areas have proven 
to be of particular relevance, including 
diabetes, chronic and acute inflammatory 
conditions and anti-infective agents. By def-
inition, this research has to be transdiscipli-
nary and we trust that authors will submit 
work which addresses this complexity using 
state-of-the art methodologies. Molecular 
biology, pharmacogenomics, genomics, 
proteonomics and related disciplines now 
offer such approaches (Efferth et al., 2008). 
When used in the context of the study of 
medicinal and food plants and their phar-
macological activities, such approaches 
offer exciting new insights which Frontiers 
in Ethnopharmacology will incorporate.
Of course, research in this field not only 
needs to comply with the ethical require-
ments of the sciences, but also with national 
and international laws relating to the pro-
tection and equitable and sustainable use 
of biodiversity and the rights of the origi-
nal keepers of this knowledge (Secretariat 
of the Convention on Biological Diversity, 
2001). This is linked to the sustainable use 
of such resource and environmental pro-
tection of the world’s biocultural diversity 
and the development of novel product for 
human and veterinary use are all aspects 
of Frontiers in Ethnopharmacology’s 
strategic focus.
Frontier in Ethnopharmacology will 
hopefully develop fast and will constantly 
incorporate changes brought about by a 
changing, continuously  globalizing and more 
and more web-based scientific world.
published (Houghton et al., 2007), which, 
however, were often not carried forward 
towards a more mechanistic biomolecu-
lar and pharmacological understanding of 
these products or their clinical development. 
Recent developments have again taken these 
challenges further and we now see an inter-
est in such clinical and more molecular biol-
ogy oriented strategies (Corson and Crews, 
2007; Graz et al., 2010).
All these are examples of ethnopharma-
cological approaches where researchers very 
successfully combined approaches from the 
chemical, biological and pharmacological 
sciences. Thus, the further development 
of these techniques using state-of-the art 
technology is another core challenge. As 
in other areas of drug discovery, translat-
ing this into products for use in biomedi-
cine has been far less successful, a problem 
which may well be overcome using these 
novel approaches.
Another core aspect of the challenge 
relates to the complexity of plants and other 
natural resources and the extracts or prod-
ucts derived from them. In the 19th century 
the initial discoveries of natural products 
started the search for novel medicines 
(Heinrich, 2010). These discoveries were 
only possible thanks to, what we would now 
call, interdisciplinary research efforts linking 
biology and chemistry with  pharmacology 
(like Claude Bernard’s work). However, 
especially during 1970’s and 1980’s studies 
identifying novel compounds from plants or 
fungi without a link to  ethnopharmacology 
are much more numerous. Frontiers in 
Ethnopharmacology encourages truly 
transdisciplinary approaches.
A wide range of innovations in phyto-
chemical analysis allowed an ever faster 
analysis and isolation of natural products 
and their identification/structure elucida-
tion. However, the complexity of mixtures 
as they are found in extracts from natural 
sources continues to be a challenge in eth-
nopharmacology/natural product research. 
TLC and later HPLC fingerprinting offered 
opportunities to characterize extracts and 
in the last two decades hyphenated tech-
niques allowed scientists to identify many of 
the metabolites in an extract in a relatively 
short period of time. It has recently been 
argued that metabolomics offers unique 
opportunities to understand such complex 
mixtures, and this is most certainly one step 
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